Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

838 - Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: non-interventional LUME-BioNIS study


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Non-Small Cell Lung Cancer


Martin Reck


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


M. Reck1, A.J. Staal-van den Brekel2, A. Mellemgaard3, N. Morsli4, K. Pietzko5, T. Kitzing6, J. Braunger6, K.M. Kerr7

Author affiliations

  • 1 Department Of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), 22927 - Grosshansdorf/DE
  • 2 Department Of Pulmonary Diseases, Twente Hospitals, Almelo/NL
  • 3 Department Of Oncology, Herlev University Hospital, Herlev/DK
  • 4 -, Boehringer Ingelheim France S.A.S., Paris/FR
  • 5 Boehringer Ingelheim Gmbh & Co. Kg, Biberach an der Riss, 88400 - Biberach/DE
  • 6 Boehringer Ingelheim Gmbh & Co. Kg, Biberach an der Riss, Biberach/DE
  • 7 Department Of Pathology, Aberdeen Royal Infirmary, AB25 2ZN - Aberdeen/GB


Abstract 838


In the Phase 3 LUME-Lung 1 trial, the addition of nintedanib to docetaxel significantly improved overall survival (OS) vs docetaxel alone in patients with adenocarcinoma non-small cell lung cancer (NSCLC) treated with one prior line of chemotherapy. No tumour or serum biomarkers are validated to predict nintedanib efficacy in this setting.

Trial design

LUME-BioNIS (NCT02671422) is an ongoing, prospective, European, multicentre, non-interventional study (N≈300) investigating whether tumour-based genomic or proteomic alterations (± clinical covariates) can predict OS in adults with advanced adenocarcinoma NSCLC initiating nintedanib + docetaxel according to the nintedanib label. Tumour tissue obtained before first-line therapy will be used for biomarker analyses. To ensure sample quality and tumour content across all slides, the first, middle and last slides will be haematoxylin/eosin-stained and assessed by a certified pathologist for tumour content, extent of necrosis and immune cell infiltration. Tumour DNA and RNA will be co-isolated from unstained slides (AllPrep® DNA/RNA FFPE Kit) and quantitated with PicoGreen® and RiboGreen® reagents, respectively. Tumour DNA sequencing libraries will be prepared using a capture-based targeted gene panel covering whole exons of NSCLC-related genes (e.g. EGFR, KRAS, ALK, BRAF, PIK3CA, TP53) and nintedanib target genes (VEGFR1–3, FGFR1–3, PDFGR α/β) and analysed by Illumina® next-generation sequencing (NGS). Transcriptomics analyses will be conducted to: (1) complement DNA analyses by providing further information on gene fusions; and (2) enable tumour classification into transcriptional subtypes. Tumour RNA libraries will be prepared and analysed by NGS or, if RNA quantity/quality is insufficient for sequencing, digital gene expression analysis (nCounter® Gene Expression Panels) will be performed. Unstained slides will also be analysed by immunohistochemistry for immune- and proliferation-related protein expression (PD-L1, Ki-67). The primary endpoint is OS, which will be analysed according to biomarker status.

Clinical trial identification


Legal entity responsible for the study

Boehringer Ingelheim Pharma GmbH & Co. KG


Boehringer Ingelheim Pharma GmbH & Co. KG


M. Reck: Author reports personal fees from Boehringer-Ingelheim, Hoffmann-La Roche, Lilly, MSD, BMS, AstraZeneca, Celgene, Merck and Pfizer. N. Morsli, K. Pietzko, T. Kitzing, J. Braunger: Author is an employee of Boehringer-Ingelheim. K.M. Kerr: Personal fees from Boehringer Ingelheim, during the conduct of the study. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.